AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14990561 — intervention group
Group type: COMPARATOR
Intervention: Baseline (BOC) before OC use at 65% Vo(2 peak)
Number of subjects: 8
Study 11412730 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90
Study 11412730 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 90
Study 9359440 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) with tocolysis and vibroacoustic stimulation
Number of subjects: 478
Study 9359440 — intervention group
Group type: COMPARATOR
Intervention: Control group (ECV not attempted)
Number of subjects: 478
Study 9359440 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful version group
Number of subjects: 478
Study 9359440 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful version group
Number of subjects: 478
Study 8504632 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dihydroxyphenylalanine infusion (0.33 micrograms min‐1 kg‐1)
Number of subjects: 12
Study 3308617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine (15 mg/kg/day for 7 days then 7.5 mg/kg/day for 14 days)
Number of subjects: 30
Study 3308617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 30
Study 3308617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3308617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine (second course)
Number of subjects: 30
Study 31350928 — intervention group
Group type: EXPERIMENTAL
Intervention: Long screw group (LSG) with 4 mm TJD
Number of subjects: 20
Study 31350928 — intervention group
Group type: COMPARATOR
Intervention: Short screw group (SSG) with 8 mm TJD
Number of subjects: 20
Study 28424081 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vegetable portion sizes (150 g instead of 75 g) and decreased meat portion sizes (average reduction of 12.5%) during the intervention period.
Number of subjects: 1006
Study 28424081 — intervention group
Group type: COMPARATOR
Intervention: Control condition with usual portion sizes of main dishes.
Number of subjects: 1006
Study 28424081 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vegetable portion sizes and decreased meat portion sizes during the intervention period.
Number of subjects: 1006
Study 26084341 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 549
Study 26084341 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (Gla‐100)
Number of subjects: 549
Study 25247740 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 240
Study 25247740 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-Tactile-Visual-Vestibular (ATVV)
Number of subjects: 240
Study 25247740 — intervention group
Group type: EXPERIMENTAL
Intervention: Any intervention (including KC and ATVV)
Number of subjects: 240
Study 25247740 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 240
Study 22938664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine and regular insulin injection (experiment group)
Number of subjects: 87
Study 22938664 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous regular insulin injection (control group)
Number of subjects: 87
Study 19283567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment (psychoactive medication)
Number of subjects: 111
Study 19283567 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacologic treatment approaches
Number of subjects: 111
Study 17602983 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 52
Study 17602983 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 52
Study 17602983 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (general)
Number of subjects: 52
Study 15220671 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum LP 01 and Bifidobacterium breve BR 03)
Number of subjects: 70
Study 15220671 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum LP 01 and Lactobacillus acidophilus LA 02)
Number of subjects: 70
Study 15220671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch powder)
Number of subjects: 70
Study 12221364 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tracheostomy (ST)
Number of subjects: 16
Study 12221364 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided percutaneous dilational tracheostomy (PDT)
Number of subjects: 16
Study 10444030 — intervention group
Group type: EXPERIMENTAL
Intervention: tcu-PA/T in patients with DIC
Number of subjects: 0
Study 10444030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin fragment 1 + 2 and urokinase antigen as predictors
Number of subjects: 0
Study 10444030 — intervention group
Group type: COMPARATOR
Intervention: Control groups (unstable angina, hip replacement, endotoxin-treated volunteers)
Number of subjects: 0
Study 7846537 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (45 mg/m2)
Number of subjects: 235
Study 7846537 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (60 mg/m2)
Number of subjects: 235
Study 7846537 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (90 mg/m2)
Number of subjects: 235
Study 2695500 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Gy daily on 20 consecutive days (total dose 60 Gy, TDF factor 123)
Number of subjects: 319
Study 2695500 — intervention group
Group type: COMPARATOR
Intervention: 4 Gy 3 times per week until 12 irradiations (total dose 48 Gy, TDF factor 103)
Number of subjects: 319
Study 353832 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (Sibelium)
Number of subjects: 40
Study 353832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30702355 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly trained in FCU with universal, routine monitoring
Number of subjects: 75
Study 30702355 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally trained in FCU with optional, variable monitoring
Number of subjects: 75
Study 30702355 — intervention group
Group type: COMPARATOR
Intervention: Services as usual with no training in the FCU
Number of subjects: 75
Study 28727591 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (daily use for 4 weeks as a primary dressing)
Number of subjects: 60
Study 28727591 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (control group)
Number of subjects: 60
Study 25730338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillary dilatation reflex amplitude (PDRA) evoked by standardized noxious test (SNT)
Number of subjects: 80
Study 25730338 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated remifentanil effect-site concentration (Ce)
Number of subjects: 80
Study 25730338 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristics curve for PDRA
Number of subjects: 80
Study 25730338 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristics curve for remifentanil Ce
Number of subjects: 80
Study 24411764 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend healthy group
Number of subjects: 146
Study 24411764 — intervention group
Group type: COMPARATOR
Intervention: Attend unhealthy group
Number of subjects: 146
Study 22980702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scalpel
Number of subjects: 198
Study 22980702 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 198
Study 19356914 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5% energy linoleic acid (LA)
Number of subjects: 100
Study 19356914 — intervention group
Group type: COMPARATOR
Intervention: 3.8% energy linoleic acid (LA)
Number of subjects: 100
Study 17641561 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for generalised anxiety disorder or anxiety neurosis
Number of subjects: 12
Study 17641561 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture for perioperative anxiety
Number of subjects: 12
Study 17641561 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12
Study 17641561 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 12
Study 15167083 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Course (n = 46)
Number of subjects: 76
Study 15167083 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 30)
Number of subjects: 76
Study 15167083 — intervention group
Group type: COMPARATOR
Intervention: Control group from a second correctional facility (n = 62)
Number of subjects: 76
Study 11778111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% combined with sufentanil 30 mcg (group S)
Number of subjects: 60
Study 11778111 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% combined with morphine 2 mg (group M)
Number of subjects: 60
Study 11778111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus sufentanil 0.5 mcg/ml (group S)
Number of subjects: 60
Study 11778111 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% plus morphine 0.02 mg/ml (group M)
Number of subjects: 60
Study 9596230 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent aspirin use
Number of subjects: 5011
Study 9596230 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent aspirin use
Number of subjects: 5011
Study 9596230 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use (frequent and infrequent)
Number of subjects: 5011
Study 9596230 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of aspirin
Number of subjects: 5011
Study 8115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay (asymptomatic)
Number of subjects: 479
Study 8115208 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA probe (symptomatic)
Number of subjects: 479
Study 8115208 — intervention group
Group type: COMPARATOR
Intervention: Culture
Number of subjects: 479
Study 8115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculture techniques
Number of subjects: 479
Study 8115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic tests
Number of subjects: 479
Study 8115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of chlamydia
Number of subjects: 479
Study 8115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infected subjects
Number of subjects: 479
Study 2576364 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride (2 mg o.d.)
Number of subjects: 119
Study 2576364 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg o.d.)
Number of subjects: 119
Study 2576364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 1278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced water diuresis
Number of subjects: 12
Study 1278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide diuresis
Number of subjects: 12
Study 1278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirst-regulated diuresis
Number of subjects: 12
Study 1278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced water diuresis (oral or parenteral fluid)
Number of subjects: 12
Study 1278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide in high dosage
Number of subjects: 12
Study 1278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide treatment
Number of subjects: 12
Study 31166412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D pre‐existing planes
Number of subjects: 20
Study 31166412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planes created from landmarks
Number of subjects: 20
Study 31166412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lines created from landmarks
Number of subjects: 20
Study 27178321 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored physical activity program for clergy
Number of subjects: 44
Study 27178321 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 44
Study 25770671 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Well (TW) intervention
Number of subjects: 31
Study 25770671 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 31
Study 23597577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 7 days prior to PCI
Number of subjects: 202
Study 23597577 — intervention group
Group type: COMPARATOR
Intervention: Immediate PCI (Control group)
Number of subjects: 202
Study 22090167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month (doses halved for patients <70 kg or intolerant)
Number of subjects: 336
Study 22090167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 336
Study 22090167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 19302423 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise training (60%-79% heart rate max reserve) for 8 weeks, 45 to 60 min/day
Number of subjects: 22
Study 17663609 — intervention group
Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 210
Study 17663609 — intervention group
Group type: EXPERIMENTAL
Intervention: Network Support + Contingency Management (NS + CM)
Number of subjects: 210
Study 17663609 — intervention group
Group type: COMPARATOR
Intervention: Case Management (CaseM)
Number of subjects: 210
Study 14749346 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NOR) 0.16 microg/kg per min
Number of subjects: 8
Study 14749346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 11687766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing with external nasal dilator strip (NBENDS)
Number of subjects: 9
Study 11687766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing with fake nasal strip (NBFNS)
Number of subjects: 9
Study 11687766 — intervention group
Group type: COMPARATOR
Intervention: Oronasal breathing (CON)
Number of subjects: 9
Study 9935260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin (intravenous alatrofloxacin followed by oral trovafloxacin for a maximum of 14 days)
Number of subjects: 226
Study 9935260 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin followed by amoxicillin/clavulanic acid (control group)
Number of subjects: 226
Study 9935260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin
Number of subjects: 226
Study 15374296 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 1000 mg/day i.m.
Number of subjects: 92
Study 15374296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 2907743 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (low-dose beta-blockade starting with 6.25 mg twice daily, increasing to a maximum of 100 mg as tolerated)
Number of subjects: 20
Study 2907743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (relative placebo group receiving standard therapy including digitalis, diuretics, vasodilators, and anticoagulants as needed)
Number of subjects: 20
Study 31864348 — intervention group
Group type: EXPERIMENTAL
Intervention: SHEMA intervention
Number of subjects: 76
Study 31864348 — intervention group
Group type: COMPARATOR
Intervention: Usual care (traditional stroke health-education)
Number of subjects: 76
Study 29780829 — intervention group
Group type: EXPERIMENTAL
Intervention: Device A
Number of subjects: 34
Study 29780829 — intervention group
Group type: COMPARATOR
Intervention: Device B
Number of subjects: 34
Study 26370724 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 2% lidocaine with epinephrine
Number of subjects: 60
Study 26370724 — intervention group
Group type: COMPARATOR
Intervention: 2 mL saline
Number of subjects: 60
Study 25160518 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus extended release (Tac-ER)
Number of subjects: 19
Study 25160518 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily tacrolimus immediate release (Tac-IR)
Number of subjects: 19
Study 22268509 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-plane treatment with 4.0 MHz, 4.5-mm depth transducer
Number of subjects: 18
Study 22268509 — intervention group
Group type: COMPARATOR
Intervention: Dual-plane treatment with 4.0 MHz, 4.5-mm depth followed by 7.0 MHz, 3.0-mm depth transducer
Number of subjects: 18
Study 22268509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both single-plane and dual-plane treatments
Number of subjects: 18
Study 19281927 — intervention group
Group type: EXPERIMENTAL
Intervention: rHDL (80 mg/kg of apolipoprotein A-I)
Number of subjects: 13
Study 19281927 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 13
Study 17940319 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent and insecticide treated bed nets
Number of subjects: 4008
Study 17940319 — intervention group
Group type: COMPARATOR
Intervention: Insecticide treated bed nets alone
Number of subjects: 4008
Study 17940319 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellent
Number of subjects: 4008
Study 15123220 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol/budesonide 2 x (4.5/160) microg
Number of subjects: 20
Study 15123220 — intervention group
Group type: COMPARATOR
Intervention: formoterol 2 x 4.5 microg
Number of subjects: 20
Study 12237626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with oral contraceptives
Number of subjects: 1698
Study 12237626 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine without oral contraceptives
Number of subjects: 1698
Study 9842788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-300 mg)
Number of subjects: 85
Study 9842788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 7989026 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO members receiving antipsychotic drugs or lithium
Number of subjects: 0
Study 2564715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 2564715 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 2564715 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 0
Study 31250099 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (2 × 1010 CFU/day of Lactobacillus acidophilus LA‐14, Lactobacillus casei LC‐11, Lactococcus lactis LL‐23, Bifidobacterium bifidum BB‐06, and Bifidobacterium lactis BL‐4)
Number of subjects: 32
Study 31250099 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 32
Study 30987658 — intervention group
Group type: EXPERIMENTAL
Intervention: Songling Xuemaikang capsules (SXC)
Number of subjects: 570
Study 30987658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 28834608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking abstinence
Number of subjects: 822
Study 28834608 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with verification at 10 ng/ml
Number of subjects: 822
Study 28834608 — intervention group
Group type: COMPARATOR
Intervention: Verification rates
Number of subjects: 822
Study 28834608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall verification failure
Number of subjects: 822
Study 26332857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.5 μg·kg IV bolus
Number of subjects: 400
Study 23320520 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1386 (95 mg single dose)
Number of subjects: 14
Study 23320520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21502898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:4 contrast water immersion (1 min of cold to 4 min of hot)
Number of subjects: 16
Study 21502898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 contrast water immersion (2.5 min of cold to 2.5 min of hot)
Number of subjects: 16
Study 21502898 — intervention group
Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 16
Study 19185254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9003 IOL
Number of subjects: 130
Study 19185254 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SN60WF IOL
Number of subjects: 130
Study 19185254 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos Adapt AO IOL
Number of subjects: 130
Study 19185254 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 aspheric IOLs
Number of subjects: 130
Study 17535945 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 495
Study 17535945 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face psychiatry
Number of subjects: 495
Study 15146408 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA therapy (including temporary high-dose prednisolone, temporary low-dose methotrexate, and sulfasalazine)
Number of subjects: 0
Study 15146408 — intervention group
Group type: COMPARATOR
Intervention: SSZ monotherapy
Number of subjects: 0
Study 11535840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent nitroglycerin ointment (n = 19)
Number of subjects: 39
Study 11535840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 39
Study 9032100 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 30
Study 8294171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8294171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.3 mg.kg-1
Number of subjects: 17
Study 8294171 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 40 micrograms.kg-1
Number of subjects: 17
Study 3565666 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education and peer support
Number of subjects: 79
Study 3565666 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education only
Number of subjects: 79
Study 3565666 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 79
Study 31844937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 0
Study 31844937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29669688 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spine thrust manipulation (TSM)
Number of subjects: 48
Study 29669688 — intervention group
Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 48